Dopaminergic involvement in effort-based but not impulsive reward processing in smokers

Drug and Alcohol Dependence

Volumn 130, Issue 1-3, 2013, Pages 109-114

  Freeman, Tom P ^a   Morgan, Celia J A ^a   Brandner, Brigitta ^b   Almahdi, Basil ^b   Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Dopamine; Effort; Impulsivity; Pramipexole; Reward responsivity; Smoking

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ABSTINENCE; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MONEY; PRIORITY JOURNAL; REWARD; SINGLE DRUG DOSE; SMOKING; TASK PERFORMANCE;

ADULT; BENZOTHIAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; PSYCHOMOTOR PERFORMANCE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; REWARD; SMOKING; SMOKING CESSATION; TIME FACTORS; YOUNG ADULT;

NICOTIANA TABACUM;

EID: 84877042490     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.10.016     Document Type: Article

References (54)

1. Acheson A., de Wit H. Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp. Clin. Psychopharmacol. 2008, 16:113-123.
2. Ahnallen C.G., Liverant G.I., Gregor K.L., Kamholz B.W., Levitt J.J., Gulliver S.B., Pizzagalli D.A., Koneru V.K., Kaplan G.B. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012, 30:9-14.
3. Al-Adawi S., Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. Addiction 1997, 92:1773-1782.
4. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008, 83:531-541.
5. Bickel W.K., Odum A.L., Madden G.J. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology 1999, 146:447-454.
6. Brody A.L., Olmstead R.E., London E.D., Farahi J., Meyer J.H., Grossman P., Lee G.S., Huang J., Hahn E.L., Mandelkern M.A. Smoking-induced ventral striatum dopamine release. Am. J. Psychiatry 2004, 161:1211-1218.
7. Chernoloz O., El Mansari M., Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009, 34:651-661.
8. Chiu P.H., Lohrenz T.M., Montague P.R. Smokers' brains compute, but ignore, a fictive error signal in a sequential investment task. Nat. Neurosci. 2008, 11:514-520.
9. Crunelle C.L., Schulz S., de Bruin K., Miller M.L., van den Brink W., Booij J. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. Eur. Neuropsychopharmacol. 2011, 21:205-210.
10. Cryan J.F., Bruijnzeel A.W., Skjei K.L., Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 2003, 168:347-358.
11. Cook J., Spring B., McChargue D., Doran N. Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report. Nicotine Tob. Res. 2010, 12:978-982.
12. Dallery J., Raiff B.R. Delay discounting predicts cigarette smoking in a laboratory model of abstinence reinforcement. Psychopharmacology 2007, 190:485-496.
13. Dawkins L., Powell J.H., West R., Powell J., Pickering A. A double-blind placebo controlled experimental study of nicotine: I - effects on incentive motivation. Psychopharmacology 2006, 189:355-367.
14. de Wit H., Enggasser J.L., Richards J.B. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 2002, 27:813-825.
15. Dutra S.J., Stoeckel L.E., Carlini S.V., Pizzagalli D.A., Evins A.E. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology 2012, 219:25-34.
16. Fehr C., Yakushev I., Hohmann N., Buchholz H.G., Landvogt C., Deckers H., Eberhardt A., Kläger M., Smolka M.N., Scheurich A., Dielentheis T., Schmidt L.G., Rösch F., Bartenstein P., Gründer G., Schreckenberger M. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am. J. Psychiatry 2008, 165:507-514.
17. Field M., Santarcangelo M., Sumnall H., Goudie A., Cole J. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology 2006, 186:255-263.
18. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
19. Hamidovic A., Kang U.J., de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J. Clin. Psychopharmacol. 2008, 28:45-51.
20. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
21. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
22. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
23. Krishnan-Sarin S., Reynolds B., Duhig A.M., Smith A., Liss T., McFetridge A., Cavallo D.A., Carroll K.M., Potenza M.N. Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend. 2007, 88:79-82.
24. Kurniawan I.T., Guitart-Masip M., Dolan R.J. Dopamine and effort-based decision making. Front. Neurosci. 2011, 5:81.
25. Leentjens A.F., Koester J., Fruh B., Shephard D.T., Barone P., Houben J.J. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin. Ther. 2009, 31:89-98.
26. Leventhal A.M., Waters A.J., Kahler C.W., Ray L.A., Sussman S. Relations between anhedonia and smoking motivation. Nicotine Tob. Res. 2009, 11:1047-1054.
27. Levin M.E., Weaver M.T., Palmatier M.I., Caggiula A.R., Sved A.F., Donny E.C. Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob. Res. 2012, 14:299-305.
28. Luo S., Ainslie G., Giragosian L., Monterosso J.R. Striatal hyposensitivity to delayed rewards among cigarette smokers. Drug Alcohol Depend. 2011, 116:18-23.
29. Martin-Sölch C., Magyar S., Künig G., Missimer J., Schultz W., Leenders K.L. Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. Exp. Brain Res. 2001, 139:278-286.
30. Mitchell S.H. Effects of short-term nicotine deprivation on decision making: delay, uncertainty, and effort discounting. Nicotine Tob. Res. 2004, 6:819-828.
31. Myerson J., Green L., Warusawitharana M. Area under the curve as a measure of discounting. J. Exp. Anal. Behav. 2001, 76:235-243.
32. Niv Y., Daw N.D., Joel D., Dayan P. Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology 2007, 191:507-520.
33. Palmatier M.I., Levin M.E., Mays K.L., Donny E.C., Caggiula A.R., Sved A.F. Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology 2009, 207:381-390.
34. Parkes J.D. Domperidone and Parkinson's disease. Clin. Neuropharmacol. 1986, 9:517-532.
35. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 1995, 51:768-774.
36. Pine A., Shiner T., Seymour B., Dolan R.J. Dopamine, time, and impulsivity in humans. J. Neurosci. 2010, 30:8888-8896.
37. Pizzagalli D.A., Evins A.E., Schetter E.C., Frank M.J., Pajtas P.E., Santesso D.L., Culhane M. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology 2008, 196:221-232.
38. Powell J.H., al-Adawi S., Morgan J., Greenwood R.J. Motivational deficits after brain injury: effects of bromocriptine in 11 patients. J. Neurol. Neurosurg. Psychiatry 1996, 60:416-421.
39. Powell J., Dawkins L., Davis R.E. Smoking, reward responsiveness, and response inhibition: tests of an incentive motivational model. Biol. Psychiatry 2002, 51:151-163.
40. Riba J., Krämer U.M., Heldmann M., Richter S., Münte T.F. Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS One 2008, 3:e2479.
41. Richardson M., Powell J.H., Curran H.V. Effects of cigarette smoking on reward responsivity and cognitive function in brain injured individuals. Neuropsychol. Rehabil. 2003, 13:365-378.
42. Robbins T.W., Everitt B.J. A role for mesencephalic dopamine in activation: commentary on Berridge (2006). Psychopharmacology 2007, 191:433-437.
43. Salamone J.D., Correa M., Farrar A., Mingote S.M. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 2007, 191:461-482.
44. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology 2006, 187:498-510.
45. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br. J. Clin. Pharmacol. 2007, 64:591-602.
46. Silber B.Y., Croft R.J., Papafotiou K., Stough C. The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 2006, 187:154-169.
47. Sweitzer M.M., Donny E.C., Dierker L.C., Flory J.D., Manuck S.B. Delay discounting and smoking: association with the Fagerström Test for Nicotine Dependence but not cigarettes smoked per day. Nicotine Tob. Res. 2008, 10:1571-1575.
48. Takahashi H., Fujimura Y., Hayashi M., Takano H., Kato M., Okubo Y., Kanno I., Ito H., Suhara T. Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int. J. Neuropsychopharmacol. 2008, 11:413-417.
49. Thompson E.R. Development and validation of an internationally reliable short-form of the positive and negative affect schedule. J. Cross Cult. Psychol. 2007, 38:227-242.
50. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry 2004, 9:557-569.
51. Voon V., Reynolds B., Brezing C., Gallea C., Skaljic M., Ekanayake V., Fernandez H., Potenza M.N., Dolan R.J., Hallett M. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology 2009, 207:645-659.
52. Wardle M.C., Treadway M.T., Mayo L.M., Zald D.H., de Wit H. Amping up effort: effects of d-amphetamine on human effort-based decision-making. J. Neurosci. 2011, 31:16597-16602.
53. Wright C.E., Sisson T.L., Ichhpurani A.K., Peters G.R. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol. 1997, 37:520-525.
54. Yi R., Landes R.D. Temporal and probability discounting by cigarette smokers following acute smoking abstinence. Nicotine Tob. Res. 2012, 14:547-558.